Evidence map›Paper›PMID 36951170›Full record

ArticleEMBO reports2023

Scalable RT-LAMP-based SARS-CoV-2 testing for infection surveillance with applications in pandemic preparedness.

Dan Lou, Matthias Meurer, Svetlana Ovchinnikova, Robin Burk, Anna Denzler, Konrad Herbst, Ioannis A Papaioannou, Yuanqiang Duan, Max L Jacobs, Victoria Witte and 19 more

Open access · bronzeAbstract read
In one paragraph

Article in EMBO reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 3 institutions in 2 countries.

Dan LouCenter for Molecular Biology of Heidelberg University (ZMBH), Heidelberg, Germany.
Matthias MeurerCenter for Molecular Biology of Heidelberg University (ZMBH), Heidelberg, Germany.ORCID 0000-0003-4651-128X
Svetlana OvchinnikovaCenter for Molecular Biology of Heidelberg University (ZMBH), Heidelberg, Germany.
Robin BurkCenter for Molecular Biology of Heidelberg University (ZMBH), Heidelberg, Germany.
Anna DenzlerCenter for Molecular Biology of Heidelberg University (ZMBH), Heidelberg, Germany.
Konrad HerbstCenter for Molecular Biology of Heidelberg University (ZMBH), Heidelberg, Germany.
Ioannis A PapaioannouCenter for Molecular Biology of Heidelberg University (ZMBH), Heidelberg, Germany.ORCID 0000-0002-8055-4024
Yuanqiang DuanCenter for Molecular Biology of Heidelberg University (ZMBH), Heidelberg, Germany.ORCID 0000-0002-4644-9706
Max L JacobsCenter for Molecular Biology of Heidelberg University (ZMBH), Heidelberg, Germany.ORCID 0000-0001-5665-9339
Victoria WitteCenter for Molecular Biology of Heidelberg University (ZMBH), Heidelberg, Germany.ORCID 0000-0002-0372-6005
Daniel ÜrgeCenter for Molecular Biology of Heidelberg University (ZMBH), Heidelberg, Germany.
Daniel KirrmaierCenter for Molecular Biology of Heidelberg University (ZMBH), Heidelberg, Germany.
Michelle KrogemannCenter for Molecular Biology of Heidelberg University (ZMBH), Heidelberg, Germany.
Krisztina GubiczaCenter for Molecular Biology of Heidelberg University (ZMBH), Heidelberg, Germany.
Kathleen BoernerDepartment of Infectious Diseases, Virology, Heidelberg University, Heidelberg, Germany.ORCID 0000-0001-7705-9375
Christian BundschuhDepartment of Infectious Diseases, Virology, Heidelberg University, Heidelberg, Germany.
Niklas M WeidnerDepartment of Infectious Diseases, Virology, Heidelberg University, Heidelberg, Germany.
Uta MerleDepartment of Gastroenterology, Heidelberg University Hospital, Heidelberg, Germany.
Britta KnorrLandratsamt Rhein-Neckar-Kreis, Gesundheitsamt, Heidelberg, Germany.
Andreas WelkerLandratsamt Rhein-Neckar-Kreis, Gesundheitsamt, Heidelberg, Germany.
Claudia M DenkingerDivision of Infectious Disease and Tropical Medicine, Heidelberg University Hospital, Heidelberg, Germany.ORCID 0000-0002-7216-7067
Paul SchnitzlerDepartment of Infectious Diseases, Virology, Heidelberg University, Heidelberg, Germany.
Hans-Georg KräusslichDepartment of Infectious Diseases, Virology, Heidelberg University, Heidelberg, Germany.
Viet Loan Dao ThiGerman Center for Infection Research (DZIF), Heidelberg, Germany.ORCID 0000-0003-2293-3592
Manuela De AllegriHeidelberg Institute of Global Health, University Hospital and Medical Faculty, Heidelberg University, Heidelberg, Germany.ORCID 0000-0002-8677-1337
Hoa Thi NguyenHeidelberg Institute of Global Health, University Hospital and Medical Faculty, Heidelberg University, Heidelberg, Germany.ORCID 0000-0001-9626-2934
Andreas DeckertHeidelberg Institute of Global Health, University Hospital and Medical Faculty, Heidelberg University, Heidelberg, Germany.ORCID 0000-0003-0526-6249
Simon AndersCenter for Molecular Biology of Heidelberg University (ZMBH), Heidelberg, Germany.ORCID 0000-0003-4868-1805
Michael KnopCenter for Molecular Biology of Heidelberg University (ZMBH), Heidelberg, Germany.ORCID 0000-0003-2566-923X
Heidelberg University · DEGerman Cancer Research Center · DEGesundheitsamt · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Throughout the SARS-CoV-2 pandemic, limited diagnostic capacities prevented sentinel testing, demonstrating the need for novel testing infrastructures. Here, we describe the setup of a cost-effective platform that can be employed in a high-throughput manner, which allows surveillance testing as an acute pandemic control and preparedness tool, exemplified by SARS-CoV-2 diagnostics in an academic environment. The strategy involves self-sampling based on gargling saline, pseudonymized sample handling, automated RNA extraction, and viral RNA detection using a semiquantitative multiplexed colorimetric reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay with an analytical sensitivity comparable with RT-qPCR. We provide standard operating procedures and an integrated software solution for all workflows, including sample logistics, analysis by colorimetry or sequencing, and communication of results. We evaluated factors affecting the viral load and the stability of gargling samples as well as the diagnostic sensitivity of the RT-LAMP assay. In parallel, we estimated the economic costs of setting up and running the test station. We performed > 35,000 tests, with an average turnover time of < 6 h from sample arrival to result announcement. Altogether, our work provides a blueprint for fast, sensitive, scalable, cost- and labor-efficient RT-LAMP diagnostics, which is independent of potentially limiting clinical diagnostics supply chains.

Indexed as

COVID-19SARS-CoV-2Clinical Laboratory TechniquesCOVID-19 TestingHumansMolecular Diagnostic TechniquesNucleic Acid Amplification TechniquesPandemicsRNA, ViralSensitivity and SpecificityRNA, Viralcorona testsCOVID-19 testspandemic preparednessRT-LAMPsurveillance testing

Identifiers

PMID36951170
PMCPMC10157315
OpenAlexW4360600314

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.